Missing a GOLDen opportunity in gastric cancer

Affiliations

Comment

Elizabeth Smyth. Lancet Oncol. 2017 Dec.

. 2017 Dec;18(12):1561-1563.

doi: 10.1016/S1470-2045(17)30719-2. Epub 2017 Nov 2.

¹ Gastrointestinal Oncology & Lymphoma Unit, Royal Marsden Hospital, London & Sutton SW3 6JJ, UK. Electronic address: elizabeth.smyth@rmh.nhs.uk.

No abstract available

Comment on

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, Shen L, Qin S, Xu N, Im SA, Locker G, Rowe P, Shi X, Hodgson D, Liu YZ, Boku N. Bang YJ, et al. Lancet Oncol. 2017 Dec;18(12):1637-1651. doi: 10.1016/S1470-2045(17)30682-4. Epub 2017 Nov 2. Lancet Oncol. 2017. PMID: 29103871 Clinical Trial.